Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 2 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Recurrence 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Muscle Invasive Bladder Cancer 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 Glioblastoma 1 Fallopian Tube Neoplasms 1 Disease 1 Advanced Solid Malignancies 1 Advanced Metastatic Breast Cancer 1 Advanced Cancer 1

Interventions

Rituximab 57 Cyclophosphamide 56 fludarabine 37 fludarabine phosphate 31 Filgrastim 27 Etoposide 22 Bortezomib 20 Melphalan 19 Gemcitabine 19 Cytarabine 17 Bendamustine Hydrochloride 17 Peripheral Blood Stem Cell Transplantation 16 Vincristine 15 pembrolizumab 14 aldesleukin 13 Prednisone 13 Doxorubicin 12 Dexamethasone 12 Busulfan 12 Whole-Body Irradiation 11 Vorinostat 11 Tacrolimus 11 Sirolimus 11 sargramostim 10 obinutuzumab 10 Lenalidomide 10 romidepsin 9 Radiotherapy 9 Rifampin 8 Paclitaxel 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Lymphoma × vistusertib × Clear all

NCT02780830 2016-09-15

INHIBITOR

AstraZeneca

Phase 1 Withdrawn

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡